{"id":52703,"date":"2024-08-08T13:38:52","date_gmt":"2024-08-08T13:38:52","guid":{"rendered":"https:\/?p=52703"},"modified":"2024-08-08T13:40:51","modified_gmt":"2024-08-08T13:40:51","slug":"novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/","title":{"rendered":"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/NVAX\">Novavax Inc (NVAX)<\/a> recently released its quarterly earnings report for the period ending June 30, 2024. As a key player in the biotechnology sector, Novavax&#8217;s performance and management analysis are critical for stakeholders and investors.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Key Insights from Novavax&#8217;s Q2 Reports:\u00a0<\/strong><\/h2>\n<p>Below are the key findings from the Novavax&#8217;s Q2 Earnings.<\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"><strong>Total Revenue:<\/strong> Reported $415.5 million for Q2 2024. Slight decrease from $424.4 million in Q2 2023<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Product Sales:<\/strong> $19.9 million in Q2 2024. Supported by steady performance in Europe and other global markets.\u00a0<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Licensing and Royalties:<\/strong> $395.6 million in Q2 2024, up from $2.2 million in Q2 2023. Reflects growing importance of strategic partnerships and licensing agreements<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Cost Management:<\/strong> Research and development expenses reduced to $106.9 million from $219.5 million in Q2 2023. Indicates ongoing efforts to optimize operational efficiencies.\u00a0<\/span><\/li>\n<\/ul>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-52707 aligncenter\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/08\/sta-analyst-rating-widget-18.png\" alt=\"NVAX analyst rating widget\" width=\"522\" height=\"317\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/sta-analyst-rating-widget-18.png 522w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/sta-analyst-rating-widget-18-300x182.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/sta-analyst-rating-widget-18-150x91.png 150w\" sizes=\"(max-width: 522px) 85vw, 522px\" \/><\/p>\n<h2><strong>Management Discussion and Analysis:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Novavax&#8217;s collaboration with Sanofi, formalized in May 2024, is a strategic milestone. This partnership includes co-commercialization of Novavax\u2019s COVID-19 vaccine and development of combination products. The upfront payment of $500 million from Sanofi significantly bolsters Novavax&#8217;s financial position and underscores the commercial potential of its vaccine portfolio.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The company\u2019s restructuring and cost reduction plan has been instrumental in improving profitability. The plan includes workforce reductions, facility consolidations, and a focused investment strategy in key vaccine programs. These measures have reduced operational expenses and enhanced overall efficiency.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Stock Target Advisor&#8217;s Analysis on Novavax:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">According to <a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a>, the average target price for Novavax Inc. is USD 18.86 over the next 12 months, with an average analyst rating of &#8220;Buy.&#8221; This outlook is based on a balanced assessment of six positive and six negative signals. Key positive signals include strong earnings performance and strategic partnerships, while negative signals encompass market volatility and dependency on a limited product range.<\/span><\/p>\n<p><strong>Recent Stock Performance:\u00a0<\/strong><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Weekly Performance: -2.10%<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Monthly Performance: -1.19%<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Yearly Performance: +50.42%<\/span><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing\"><img decoding=\"async\" class=\"aligncenter wp-image-48710 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/05\/CTA-for-STA.jpg\" alt=\"CTA for STA\" width=\"1200\" height=\"350\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/05\/CTA-for-STA.jpg 1200w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/05\/CTA-for-STA-300x88.jpg 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/05\/CTA-for-STA-1024x299.jpg 1024w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/05\/CTA-for-STA-150x44.jpg 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/05\/CTA-for-STA-768x224.jpg 768w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<h2><strong>Conclusion:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Novavax Inc.&#8217;s Q2 2024 earnings report highlights a period of significant financial and strategic progress. The company\u2019s ability to secure substantial licensing revenues, coupled with effective cost management, has strengthened its financial foundation. Strategic partnerships, particularly with Sanofi, are poised to drive future growth and innovation. <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novavax Inc (NVAX) recently released its quarterly earnings report for the period ending June 30, 2024. As a key player in the biotechnology sector, Novavax&#8217;s&#8230;<\/p>\n","protected":false},"author":17,"featured_media":52712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-52703","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge\" \/>\n<meta property=\"og:description\" content=\"Novavax Inc (NVAX) recently released its quarterly earnings report for the period ending June 30, 2024. As a key player in the biotechnology sector, Novavax&#8217;s...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-08T13:38:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-08T13:40:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/STAs-Blog-Images-2024-08-08T184022.441.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge\",\"datePublished\":\"2024-08-08T13:38:52+00:00\",\"dateModified\":\"2024-08-08T13:40:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\",\"name\":\"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-08-08T13:38:52+00:00\",\"dateModified\":\"2024-08-08T13:40:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/","og_locale":"en_US","og_type":"article","og_title":"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge","og_description":"Novavax Inc (NVAX) recently released its quarterly earnings report for the period ending June 30, 2024. As a key player in the biotechnology sector, Novavax&#8217;s...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-08-08T13:38:52+00:00","article_modified_time":"2024-08-08T13:40:51+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/08\/STAs-Blog-Images-2024-08-08T184022.441.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge","datePublished":"2024-08-08T13:38:52+00:00","dateModified":"2024-08-08T13:40:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/","name":"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-08-08T13:38:52+00:00","dateModified":"2024-08-08T13:40:51+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novavax-q2-2024-earnings-revenue-dips-despite-licensing-surge\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Novavax Q2 2024 Earnings: Revenue Dips Despite Licensing Surge"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=52703"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52703\/revisions"}],"predecessor-version":[{"id":52711,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52703\/revisions\/52711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/52712"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=52703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=52703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=52703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}